Borstkanker Onderzoek Groep

This study tests whether doctors can safely reduce the amount of chemotherapy given before surgery for HER2-positive breast cancer by using imaging scans to guide decisions. About 462 participants with stage II or III disease will receive a tailored treatment plan. The goal is to…

This study tests whether adding alpelisib to continued fulvestrant can help people with a specific type of advanced breast cancer (PIK3CA-mutated, HR+ HER2-) whose disease has worsened while on fulvestrant alone. About 130 adults whose cancer progressed on fulvestrant (with or wi…

This study looks at the best time to add a CDK4/6 inhibitor to hormone therapy for women with advanced hormone-receptor-positive breast cancer. About 1,050 participants will either get the drug combination as their first treatment or wait until their second line of therapy. The g…

This study tests a drug called trifluridine/tipiracil in 52 women with advanced ER-positive, HER2-negative breast cancer that can't be cured with surgery or radiation. Participants had already received certain chemotherapies. The goal is to see if the drug can slow cancer growth …

This study tests whether a combination of two drugs (ribociclib and letrozole) can replace chemotherapy before surgery for postmenopausal women with a common type of breast cancer (hormone receptor positive, HER2 negative). About 100 women with stage II or III breast cancer will …